Are the effects of blood pressure lowering treatment diminishing?: meta-regression analyses

Clinical Hypertension

Table 3 Meta-regression analyses (Dependent variable: natural log of relative risk for stroke)

	Model 1S (single)			Model 2S (multiple)
Variable	exp(b)	95% CI	p-value	exp(b)	95% CI	p-value
Trial start year (per 10 years)	1.12	1.06–1.19	< 0.001	1.07	0.97–1.19	0.154
	Adjusted R² = 50.5%
Age (per 10 years)	1.02	0.93–1.13	0.642	1.00	0.89–1.12	0.973
	Adjusted R² = −1.5%
Sample size (per 1000 participants)	1.01	1.00–1.02	0.005	1.00	0.99–1.01	0.509
	Adjusted R² = 30.9%
Baseline SBP (per 10 mmHg)	0.94	0.91–0.98	0.003	1.03	0.97–1.09	0.399
	Adjusted R² = 28.4%
SBP difference (per 10 mmHg)	0.78	0.71–0.86	< 0.001	0.81	0.69–0.94	0.008
	Adjusted R² = 60.5%
Region (per category)
Mixed region	1 (ref)			1 (ref)
North America	0.81	0.68–0.97	0.024	1.05	0.85–1.29	0.649
Europe	0.81	0.69–0.94	0.008	0.97	0.81–1.17	0.782
Asia	0.78	0.66–0.93	0.005	0.83	0.70–0.99	0.042
Oceania	0.89	0.46–1.70	0.713
	Adjusted R² = 40.2%
Adjusted R²				79.8%
K				67

exp(b) the exponentiation of the b coefficient; ref. reference; CI confidence interval; K number of trials

ISSN: 2056-5909